SCOPUS 정보 검색 플랫폼

Volumn 12, Issue 64, 2003, Pages 55-57

For some cases of severe sepsis?

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CENTOXIN; DROTRECOGIN;

ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG MANUFACTURE; DRUG WITHDRAWAL; FATALITY; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; MORTALITY; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SEPSIS; TREATMENT OUTCOME;

EID: 0037939862 PISSN: 11677422 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (2)

References (9)

1
- 0026710191
- "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis"
- The ACCP/SCCM consensus conference committee
- The ACCP/SCCM consensus conference committee "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis" Chest 1992; 101 (6): 1644-1655.
- (1992) Chest , vol.101 , Issue.6 , pp. 1644-1655

2
- 0035826080
- "Severe sepsis. A new treatment with both anticoagulant and antiinflammatory properties"
- Matthay MA "Severe sepsis. A new treatment with both anticoagulant and antiinflammatory properties" N Engl J Med 2001: 344 (10): 759-762.
- (2001) N. Engl. J. Med. , vol.344 , Issue.10 , pp. 759-762
- Matthay, M.A.¹

3
- 0037045333
- "La protéine C: Un nouveau traitement pour les sepsis et les méningococcémies sévères"
- Regazzoni S et al. "La protéine C: un nouveau traitement pour les sepsis et les méningococcémies sévères" Méd Hyg 2002; 60: 42-44.
- (2002) Méd. Hyg. , vol.60 , pp. 42-44
- Regazzoni, S.¹

4
- 0035826096
- "Efficacy and safety of recombinant human activated protein C for severe sepsis"
- + 345 (3): 219-220
- Bernard GR et al. "Efficacy and safety of recombinant human activated protein C for severe sepsis" N Engl J Med 2001; 344 (10): 699-709 + 345 (3): 219-220.
- (2001) N. Engl. J. Med. , vol.344 , Issue.10 , pp. 699-709
- Bernard, G.R.¹

5
- 85009030123
- "Drotrecogin alfa (activated) [recombinant human activated protein C (rhACP)] Xigris°"
- FDA briefing document: anti-infective advisory committee. BLA # 125029/0 September 12
- FDA briefing document: anti-infective advisory committee "drotrecogin alfa (activated) [recombinant human activated protein C (rhACP)] Xigris°" BLA # 125029/0 September 12, 2001: 117 pages.
- (2001) , pp. 117

6
- 0009201427
- "Briefing document for Xigris° for the treatment of severe sepsis"
- and Company, 6 August
- Eli Lilly and Company "Briefing document for Xigris° for the treatment of severe sepsis" 6 August 2001: 189 pages.
- (2001) , pp. 189
- Lilly, E.¹

7
- 85009033432
- "Drotrecogin alfa (activated) in severe sepsis patients with 2 or more organ dysfunctions"
- European Society of Intensive Care Medicine, 15th Annual Congress, Barcelona, 29 September-2 October abstract 307
- Dhainaut J et al. "Drotrecogin alfa (activated) in severe sepsis patients with 2 or more organ dysfunctions" European Society of Intensive Care Medicine, 15th Annual Congress, Barcelona, 29 September-2 October 2002: abstract 307 (1 page).
- (2002) , pp. 1
- Dhainaut, J.¹

8
- 0037179685
- "Risks and benefits of activated protein c treatment for severe sepsis"
- Shaw Warren H et al. "Risks and benefits of activated protein c treatment for severe sepsis" N Engl J Med 2002; 347 (13): 1027-1030.
- (2002) N. Engl. J. Med. , vol.347 , Issue.13 , pp. 1027-1030
- Shaw Warren, H.¹

9
- 85009029716
- "Xigris 5 mg - Xigris 20 mg - Dossier de transparence"
- Lilly September
- Lilly "Xigris 5 mg - Xigris 20 mg - dossier de transparence" September 2002: 192 pages.
- (2002) , pp. 192

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.